Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Breast Neoplasms 1

Interventions

pembrolizumab 9Gemcitabine 9Cyclophosphamide 8Radiotherapy 7Carboplatin 7Paclitaxel 6Cisplatin 6Trastuzumab 5Irinotecan 5Doxorubicin 5Docetaxel 5Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Capecitabine 4poly ICLC 3pazopanib 3liposomal doxorubicin 3durvalumab 3atezolizumab 3Therapeutics 3Taxes 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Oncolytic Virotherapy 3Letrozole 3Injections 3Fulvestrant 3Fluorodeoxyglucose F18 3Flow Cytometry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × SGN-LIV1A × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡